Skip to main content
Find a DoctorGet Care Now
Skip to main content






What You Need to Know About the PALB2 Breast Cancer Gene

Thursday, October 7, 2021


Yale Cancer Center and Smilow Cancer Hospital experts explain why this gene can increase your breast cancer risk

New Haven, CT — Most of us have heard about the BRCA1 and BRCA2 genes. Men and women with a personal and/or family history of breast cancer have been offered testing for mutations in these two genes for a number of years to determine if they are at greater risk for breast and other cancers. But what about the PALB2 gene, which stands for Partner And Locator of BRCA2? A recent study in the New England Journal of Medicine showed women who carry a mutation in the PALB2 gene were 35% more likely to be diagnosed with breast cancer by age 70, compared with women who don't carry the mutation.

“PALB2 is a gene that encodes a BRCA2-interacting protein. The BRCA2-PALB2 interaction is necessary for DNA damage repair that normally happens in our cells,” said Mariya Rozenblit, MD, Instructor of Medicine (Medical Oncology) at Yale Cancer Center. “When this protein is not functioning normally, DNA damage is not fixed, and cells become abnormal, leading to cancer.”  

Rozenblit said patients are becoming more aware of genetic testing and its importance in determining their breast cancer risk. If they have concerns, she recommends women discuss testing with their primary care doctor and see a genetic counselor if needed. Patients counseled by the Smilow Cancer Genetics & Prevention Program are referred based on their personal and/or family history of cancer. A genetic counselor will take a thorough family history and recommend the most appropriate genetic test(s), which are often performed through a blood test. Genetic tests to evaluate for hereditary breast cancer risk now often consist of a panel of genes, including BRCA1, BRCA2, PALB2, and others. 

“Results of genetic testing typically take two to three weeks and the genetic counselor will review the results of the genetic testing and their implications with the patient,” said Claire Healy, MS, CGC, Co-Manager Genetic Counselor for the Smilow Cancer Genetics and Prevention Program. “If a mutation is identified the genetic counselor can also help connect the patient to providers for high-risk cancer screening and medical management, if needed.”
Healy added that clinical testing of PALB2 has not been available for as long as genetic testing of the BRCA1 and BRCA2 genes, so patients who completed testing prior to 2013 may not have had an analysis including the PALB2 gene. These patients should consider discussing with their providers whether additional genetic testing is indicated.

“One of the BEST things patients can do if they are worried about their risk to develop cancer is ensure that they have collected detailed information about their family history,” said Healy. “Ideally, patients should be aware of who in their family has had cancer, the type of cancer their relative was diagnosed with, i.e. in which organ the cancer started, and the age at which they were diagnosed.”
Visit the Cancer Genetics and Prevention Program for more information on genetic testing and counseling at Smilow Cancer Hospital and Yale Cancer Center. 


Yale New Haven Health (YNHHS), the largest and most comprehensive healthcare system in Connecticut, is recognized for advanced clinical care, quality, service, cost effectiveness and commitment to improving the health status of the communities it serves. YNHHS includes five hospitals – Bridgeport, Greenwich, Lawrence + Memorial, Westerly and Yale New Haven hospitals, several specialty networks and Northeast Medical Group, a non-profit medical foundation with several hundred community-based and hospital-employed physicians. YNHHS is affiliated with Yale University and Yale Medicine, the clinical practice of the Yale School of Medicine and the largest academic multi-specialty practice in New England. Yale New Haven Hospital is the primary teaching hospital of Yale School of Medicine.

Similar Articles


Avangrid Foundation Joins Bridgeport Hospital’s Effort to Reduce Cancer Screening Disparities with $25,000 Grant

BRIDGEPORT, CT (February 2024) – The Bridgeport Hospital Foundation is proud to announce a $25,000 gift from the Avangrid Foundation, the philanthropic arm of United Illuminating and Southern Connecticut Gas’ parent company, Avangrid.


Yale New Haven Health announces Pamela Sutton-Wallace as the new president of Yale New Haven Health

New Haven, CT (February 20, 2024) – Yale New Haven Health today announced that Pamela Sutton-Wallace has been promoted to president of Yale New Haven Health.


Yale New Haven Health announces Katherine Heilpern, MD, as the new president of Yale New Haven Hospital

New Haven, CT (February 15, 2024) – Today, Yale New Haven Health announced the appointment of Katherine Heilpern, MD, FACEP, as the new president of Yale New Haven Hospital, the Health System’s flagship hospital, effective March 11.